Analysts Set Zenas BioPharma, Inc. (NASDAQ:ZBIO) Price Target at $44.29

Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) have been given an average recommendation of “Moderate Buy” by the nine analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $44.2857.

ZBIO has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $44.00 target price on shares of Zenas BioPharma in a report on Friday, May 15th. Wall Street Zen raised Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Guggenheim increased their price objective on Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a report on Friday, March 27th. Finally, Citigroup reissued a “buy” rating on shares of Zenas BioPharma in a report on Thursday, May 14th.

Zenas BioPharma Stock Up 1.4%

NASDAQ:ZBIO opened at $19.84 on Friday. The firm has a market capitalization of $1.25 billion, a PE ratio of -2.34 and a beta of -0.61. The stock has a 50 day moving average of $20.64 and a 200-day moving average of $26.40. Zenas BioPharma has a 52 week low of $8.91 and a 52 week high of $44.60. The company has a current ratio of 11.94, a quick ratio of 11.94 and a debt-to-equity ratio of 1.04.

Zenas BioPharma (NASDAQ:ZBIO) last posted its earnings results on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.01. During the same period in the prior year, the business earned ($0.80) EPS. Analysts predict that Zenas BioPharma will post -4.47 EPS for the current year.

Insider Buying and Selling

In other Zenas BioPharma news, Director Fairmount Funds Management Llc acquired 150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 31st. The stock was acquired at an average cost of $20.00 per share, with a total value of $3,000,000.00. Following the acquisition, the director directly owned 2,359,025 shares of the company’s stock, valued at $47,180,500. This represents a 6.79% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Hongbo Lu acquired 3,768 shares of the firm’s stock in a transaction that occurred on Tuesday, March 31st. The stock was acquired at an average cost of $18.63 per share, with a total value of $70,197.84. Following the completion of the acquisition, the director directly owned 426,736 shares in the company, valued at approximately $7,950,091.68. This represents a 0.89% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 273,768 shares of company stock valued at $5,150,198 in the last three months. 22.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zenas BioPharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new position in Zenas BioPharma in the 4th quarter worth approximately $38,000. Quarry LP lifted its position in Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after purchasing an additional 291 shares during the period. Russell Investments Group Ltd. acquired a new stake in Zenas BioPharma in the third quarter worth approximately $30,000. CWM LLC lifted its position in Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after purchasing an additional 709 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Zenas BioPharma in the fourth quarter worth approximately $95,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.